Erdosteine
Erdosteine inhibits lipopolysaccharide (LPS) -induced NF-κB activation[1][2]. Erdosteine has muco-modulatory, anti-bacterial, anti-inflammatory and anti-oxidant effects[3].
Product Specifications
CAS Number
84611-23-4
Product Name Alternative
RV 144
UNSPSC
12352005
Hazard Statement
H302, H315, H319, H335
Target
Bacterial; NF-κB
Type
Reference compound
Related Pathways
Anti-infection; NF-κB
Applications
Metabolism-sugar/lipid metabolism
Field of Research
Infection; Metabolic Disease; Inflammation/Immunology
Assay Protocol
https://www.medchemexpress.com/Erdosteine.html
Purity
99.83
Solubility
DMSO : 50 mg/mL (ultrasonic) |H2O : 6.67 mg/mL (ultrasonic)
Smiles
O=C(O)CSCC(NC(CCS1)C1=O)=O
Molecular Formula
C8H11NO4S2
Molecular Weight
249.31
Precautions
H302, H315, H319, H335
References & Citations
[1]Park JS, et al. Anti-inflammatory Effect of Erdosteine in Lipopolysaccharide-Stimulated RAW 264.7 Cells. Inflammation. 2016 Aug;39 (4) :1573-81.|[2]Oktar S, et al. Beneficial effect of erdosteine on methotrexate-induced testicular toxicity in mice. Toxicol Ind Health. 2010 Aug;26 (7) :433-8.|[3]Recipharm’s proprietary molecule Erdosteine recognised as COPD treatment
Shipping Conditions
Room Temperature
Storage Conditions
-20°C, 3 years; 4°C, 2 years (Powder)
Scientific Category
Reference compound1
Clinical Information
Launched
Isoform
NF-κB
Available Sizes
Frequently Asked Questions
More Discoveries
Explore Other Products
Browse additional items from our catalog
